Related Experiment Video
Updated: May 19, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
Published on: March 23, 2016
Longitudinal Multi-Omics Profiling of Aqueous Humor Implicates GALNS Depletion as a Pro-Fibrotic Mediator of
Yujuan Huang1,2, Mi Gui1, Xiangbin Kong2
1Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China.
Purpose:
Preoperative anti-vascular endothelial growth factor (VEGF) therapy in proliferative diabetic retinopathy (PDR) may exacerbate fibrovascular contraction, posing significant challenges. This study aims to characterize proteo-metabolomic changes induced by anti-VEGF therapy, validate key candidates on orthogonal analytical platforms, and provide functional evidence for the lead molecule.
Methods:
Aqueous humor from 25 patients with PDR with simple vitreous hemorrhage (VH; n = 13) or VH with tractional retinal detachment (VH + TRD; n = 12) underwent data-independent acquisition (DIA) proteomics and widely targeted metabolomics before and 7 days after intravitreal aflibercept. Molecules altered in both cross-sectional and longitudinal comparisons were classified as "aggravation-type" or "improvement-type." Aggravation-type molecules were validated by parallel reaction monitoring/selected reaction monitoring (PRM/SRM) in an independent cohort (cataract controls, n = 10; simple VH, n = 5; VH + TRD, n = 5), and GALNS was functionally assessed by siRNA knockdown in fibroblasts.
Results:
Intersection analysis identified 38 molecules (5 proteins and 33 metabolites): 35 improvement-type and 3 aggravation-type (CAST, GALNS, and 3-hydroxypropanoic acid [3-HPA]). Independent validation using PRM proteomics and SRM metabolomics confirmed that only GALNS was robustly validated across both cross-sectional (P = 0.016) and longitudinal (P = 0.049) comparisons, whereas CAST and 3-HPA did not reach statistical significance in validation. GALNS exhibited a biphasic pattern-elevated in PDR relative to cataract controls yet depleted in VH + TRD and further declined post-treatment. GALNS knockdown in fibroblasts upregulated α-SMA and collagen I, accelerated migration, and enhanced contractility.
Conclusions:
This multi-omics study, reinforced by independent validation, reveals GALNS depletion as a potential pro-fibrotic molecule following anti-VEGF therapy in PDR, offering a promising candidate for perioperative risk stratification. CAST and 3-HPA remain exploratory candidates requiring validation in larger cohorts.
Insights
Anti-vascular endothelial growth factor (VEGF) therapy for proliferative diabetic retinopathy (PDR) may worsen fibrosis. This study identified GALNS depletion as a potential pro-fibrotic marker after anti-VEGF treatment in PDR patients.
Area of Science:
- Ophthalmology
- Molecular Biology
- Biochemistry
Background:
- Preoperative anti-vascular endothelial growth factor (VEGF) therapy in proliferative diabetic retinopathy (PDR) can lead to fibrovascular contraction, complicating treatment.
- Understanding the molecular changes induced by anti-VEGF therapy is crucial for managing PDR complications.
Purpose of the Study:
- To characterize proteo-metabolomic alterations following anti-VEGF therapy in PDR.
- To validate potential molecular candidates associated with PDR progression or improvement.
- To investigate the functional role of key molecules in fibrosis.
Main Methods:
- Aqueous humor samples from PDR patients were analyzed using data-independent acquisition (DIA) proteomics and widely targeted metabolomics before and after anti-VEGF (aflibercept) treatment.
- Molecules showing significant changes were classified as 'aggravation-type' or 'improvement-type'.
- Validation was performed using parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) in an independent cohort, with functional assessment of GALNS via siRNA knockdown.
Main Results:
- Thirty-eight molecules, including 5 proteins and 33 metabolites, were identified. Three molecules (CAST, GALNS, 3-hydroxypropanoic acid [3-HPA]) were classified as 'aggravation-type'.
- Only GALNS was robustly validated across cross-sectional and longitudinal analyses, showing depletion post-treatment in PDR patients with tractional retinal detachment.
- GALNS knockdown in fibroblasts increased pro-fibrotic markers (α-SMA, collagen I), enhanced cell migration, and promoted contractility.
Conclusions:
- GALNS depletion is identified as a potential pro-fibrotic molecule associated with anti-VEGF therapy in PDR.
- GALNS may serve as a candidate biomarker for perioperative risk stratification in PDR patients undergoing anti-VEGF treatment.
- CAST and 3-HPA require further investigation in larger cohorts.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment
